Scientific evidence and financial obligations to ensure access to biosimilars for cancer treatment

JAMA - Journal of the American Medical Association

Volumn 317, Issue 1, 2017, Pages 33-34

  Bauchner, Howard ^a   Fontanarosa, Phil B ^a   Golub, Robert M ^a  

^a JAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT; TRASTUZUMAB;

CANCER SURVIVAL; CANCER THERAPY; CLINICAL DECISION MAKING; DRUG EFFICACY; EDITORIAL; HUMAN; MALIGNANT NEOPLASM; METASTATIC BREAST CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; NEOPLASMS;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; HUMANS; NEOPLASMS; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85008386006     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.18743     Document Type: Editorial

References (7)

1. Rugo HS, Barve A,Waller CF, et al; Heritage Study Investigators. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positivemetastatic breast cancer: a randomized clinical trial. JAMA. doi:10.1001/jama.2016.18305
2. Norton A. Herceptin may benefit some women with early breast cancer. https://consumer.healthday.com/cancer-information-5/breast-cancer-news-94/herceptin-may-benefit-some-women-with-early-breast-cancer-695287.html. Accessed November 18, 2016.
3. Lyon J. Significant increases in EpiPen price. JAMA. 2016;316(14):1439.
4. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316 (8):858-871.
5. Green AK, Wood WA, Basch EM. Time to reassess the cancer compendia for off-label drug coverage in oncology. JAMA. 2016;316(15):1541-1542.
6. Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016;17(11):e502-e509.
7. Mylan. Mylan and Biocon announce U.S. FDA submission for proposed biosimilar trastuzumab. http://newsroom.mylan.com/2016-11-08-Mylan-and-Biocon-Announce-U-S-FDA-Submission-for-Proposed-Biosimilar-Trastuzumab. Accessed November 18, 2016.